Latest Articles
Gesynta Pharma Receives $27 Million For Endometriosis Novel Therapy Drug - Forbes
Gesynta Pharma Receives $27 Million For Endometriosis Novel Therapy Drug Forbes
Published: Feb. 13, 2025, 5:04 p.m.
FREE WEBINAR Harnessing the Power of CBD: Enhancing Women’s Health Through Cannabinoid Therapy Featuring Dr. Chloe Weber, DACM, L.Ac. – Lhasa OMS Blog - Lhasa OMS
FREE WEBINAR Harnessing the Power of CBD: Enhancing Women’s Health Through Cannabinoid Therapy Featuring Dr. Chloe Weber, DACM, L.Ac. – Lhasa OMS Blog Lhasa OMS
Published: Feb. 13, 2025, 3:20 p.m.
Short- vs Standard-Course Radiation Therapy for Endometrial Cancer - The ASCO Post
Short- vs Standard-Course Radiation Therapy for Endometrial Cancer The ASCO Post
Published: Feb. 12, 2025, 5:48 p.m.
Short-Course Radiation Therapy Effective for Endometrial Cancer Patients | Newswise - Newswise
Short-Course Radiation Therapy Effective for Endometrial Cancer Patients | Newswise Newswise
Published: Feb. 12, 2025, 2:05 a.m.
Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective - News-Medical.Net
Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective News-Medical.Net
Published: Feb. 12, 2025, 1:49 a.m.
Short-course radiation matches standard therapy for endometrial cancer - Medical Xpress
Short-course radiation matches standard therapy for endometrial cancer Medical Xpress
Published: Feb. 11, 2025, 8:52 p.m.
Short-Course Radiation Therapy Effective for Endometrial Cancer Patients - University of Utah Health Care
Short-Course Radiation Therapy Effective for Endometrial Cancer Patients University of Utah Health Care
Published: Feb. 11, 2025, 5 p.m.
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today
ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? Medpage Today
Published: Feb. 5, 2025, 7:31 p.m.
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today
Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today
Published: Feb. 5, 2025, 5:54 p.m.
Link copied to clipboard!